OBJECTIVES: To estimate the average annual cost of health services use related to Chronic Venous Disease (CVD) according to their classification

METHODS: The records between 2015 to 2020 from an institution that provide services were analyzed, which allowed us to know the CEAP (clinical-etiological-Anatomical-physiopathological) qualification, procedures and pharmacological treatments applied to patients. A sample were used with ICD-10 codes from I80 to I89. According to the CEAP clinical classification, the frequencys of an average patient was validated by two leading vascular pyscisians at national level. These were converted into costs using the Social Security Institute fare manual 2001 + 30% (of each rate) and the prices of Integrated System for the Supply of Medicines and Medical-Surgical of Colombia. Costs were expressed in American dollars using an average exchange rate of USD$ = 3,743 COP of 2021.

RESULTS: 388 patients (85.57% female) with a median age of 64 years (IQR 57 - 69.25) and males with an age of 66.5 years (IQR 58.75 - 71.25) were analyzed. The clinical characterization was C0 (34.79%), C1 (5.67%), C2 (31.44%), C3 (9.79%), C4 (6.19%), C5 (2.32%) and C6 (9.79%). On average, the annual cost per patient is C0 ($53,16), C1 ($130.11), C2 ($490.26), C3 ($952.46), C4 ($955.17), C5 ($1,128.29) and C6 ($1,292.83). The procedure service group concentrates from 42.17% of the total annual cost per C2 patient to 77.78% of the annual cost per patient in C6. Pharmacological treatments begin from C2, with Diosmin/hesperidin 450+50 mg being the most formulated.

CONCLUSIONS: Analyzing standard costing allows decisions to be made for the proper use of resources in health services related to CVD care